Published in Mayo Clin Proc on July 01, 2000
Liver enzyme alteration: a guide for clinicians. CMAJ (2005) 3.42
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology (2009) 2.75
Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis (2011) 1.68
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther (2011) 1.52
Primary sclerosing cholangitis. Can J Gastroenterol (2008) 1.17
Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol (2010) 1.08
Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. Hepatology (2015) 1.00
Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol (2013) 0.98
Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol (2008) 0.94
Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. J Crohns Colitis (2014) 0.91
Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk. Gastroenterol Rep (Oxf) (2014) 0.87
Primary sclerosing cholangitis: diagnosis and treatment. Dtsch Arztebl Int (2013) 0.87
Liver disorders in inflammatory bowel disease. Gastroenterol Res Pract (2012) 0.85
IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis. Clin Exp Immunol (2003) 0.85
Current status of therapy in autoimmune liver disease. Therap Adv Gastroenterol (2009) 0.83
Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol (2013) 0.82
S100A9 is a biliary protein marker of disease activity in primary sclerosing cholangitis. PLoS One (2012) 0.81
Steroid-responsive (autoimmune?) sclerosing cholangitis. Dig Dis Sci (2005) 0.81
The predictors of the presence of varices in patients with primary sclerosing cholangitis. Hepatology (2010) 0.80
Impact of transjugular intrahepatic portosystemic shunt on post-colectomy complications in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterol Rep (Oxf) (2014) 0.80
Hepatic ADC map as an adjunct to conventional abdominal MRI to evaluate hepatic fibrotic and clinical cirrhotic severity in biliary atresia patients. Eur Radiol (2015) 0.79
Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. Ann Hepatol (2014) 0.79
Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol (2015) 0.78
Performance of magnetic resonance elastography in primary sclerosing cholangitis. J Gastroenterol Hepatol (2016) 0.78
Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis. Am J Ther (2014) 0.76
Controversies in the management of primary sclerosing cholangitis. World J Hepatol (2016) 0.76
Individuals with Primary Sclerosing Cholangitis Have Elevated Levels of Biomarkers for Apoptosis but Not Necrosis. Dig Dis Sci (2015) 0.76
Emerging pharmacologic therapies for primary sclerosing cholangitis. Curr Opin Gastroenterol (2017) 0.75
A review of the medical treatment of primary sclerosing cholangitis in the 21st century. Ther Adv Chronic Dis (2016) 0.75
Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge. Hepatol Int (2016) 0.75
Correlation between findings on MRCP and gadolinium-enhanced MR of the liver and a survival model for primary sclerosing cholangitis. Dig Dis Sci (2007) 0.75
Evaluation of Biliary Calprotectin as a Biomarker in Primary Sclerosing Cholangitis. Medicine (Baltimore) (2016) 0.75
[Liver biopsy at the intersection of clinical and pathological diagnosis]. Pathologe (2008) 0.75
Cholangitis: Diagnosis, Treatment and Prognosis. J Clin Transl Hepatol (2017) 0.75
Functional gadoxetate disodium-enhanced MRI in patients with primary sclerosing cholangitis (PSC). Eur Radiol (2015) 0.75
Elevated trimethylamine-N-oxide (TMAO) is associated with poor prognosis in primary sclerosing cholangitis patients with normal liver function. United European Gastroenterol J (2016) 0.75
A model to predict survival in patients with end-stage liver disease. Hepatology (2001) 18.06
Biliary tract cancers. N Engl J Med (1999) 6.36
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology (1999) 5.75
The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut (2009) 4.01
Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med (1993) 3.83
MELD and PELD: application of survival models to liver allocation. Liver Transpl (2001) 3.76
Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology (1980) 3.57
Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA (2000) 3.15
Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA (1999) 2.78
Cryptosporidium parvum is cytopathic for cultured human biliary epithelia via an apoptotic mechanism. Hepatology (1998) 2.75
A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med (1997) 2.66
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol (1978) 2.63
High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol (2001) 2.61
Splenosis: autotransplantation of splenic tissue. Am J Med (1976) 2.53
Unsedated small-caliber esophagogastroduodenoscopy (EGD) versus conventional EGD: a comparative study. Gastroenterology (1999) 2.44
Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology (1989) 2.39
Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res (2000) 2.38
Diagnosis and monitoring of Whipple disease by polymerase chain reaction. Ann Intern Med (1997) 2.38
Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med (1991) 2.37
Current concepts. Primary sclerosing cholangitis. N Engl J Med (1984) 2.35
Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl (2000) 2.27
The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol (2000) 2.25
Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics (1995) 2.19
The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol (1999) 2.18
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol (2001) 2.11
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology (1994) 2.10
Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology (1991) 2.06
Cost-effectiveness of ultrasound-guided liver biopsy. Hepatology (1998) 2.06
Secular trends in hip fracture incidence and recurrence. Osteoporos Int (2008) 2.04
Optimists vs pessimists: survival rate among medical patients over a 30-year period. Mayo Clin Proc (2000) 2.02
Intrapulmonary vascular dilatations (IPVD) in liver transplant candidates. Screening by two-dimensional contrast-enhanced echocardiography. Chest (1990) 1.99
Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med (1989) 1.94
Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol (2000) 1.93
Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc (1989) 1.93
Isolation and morphologic characterization of bile duct epithelial cells from normal rat liver. Gastroenterology (1989) 1.89
Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology (1982) 1.88
Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism, and biliary excretion. J Clin Invest (1987) 1.88
Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology (1996) 1.87
Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant (2008) 1.86
Monooctanoin, a dissolution agent for retained cholesterol bile duct stones: physical properties and clinical application. Gastroenterology (1980) 1.84
Variant forms of cholestatic diseases involving small bile ducts in adults. Am J Gastroenterol (2000) 1.83
A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med (1990) 1.81
Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther (2013) 1.79
Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg (1991) 1.78
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia (2008) 1.77
Morphological, molecular, and functional heterogeneity of cholangiocytes from normal rat liver. Gastroenterology (1996) 1.76
Dysphagia without endoscopically evident disease: to dilate or not? Am J Gastroenterol (2001) 1.76
Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology (1990) 1.76
Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol (1990) 1.74
A prospective comparison of molecular diagnostic techniques for the early detection of cytomegalovirus in liver transplant recipients. J Infect Dis (1995) 1.71
Whipple's disease: clinical, biochemical, and histopathologic features and assessment of treatment in 29 patients. Mayo Clin Proc (1988) 1.71
Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol (2000) 1.70
Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology (1990) 1.69
Detection of cytomegalovirus DNA in sera of liver transplant recipients. J Clin Microbiol (1994) 1.69
Long-term trends in hip fracture prevalence: the influence of hip fracture incidence and survival. Osteoporos Int (1998) 1.69
Heterogeneity of the proliferative capacity of rat cholangiocytes after bile duct ligation. Am J Physiol (1998) 1.68
The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg (1997) 1.68
Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig Dis Sci (2001) 1.65
Recent advances in the isolation of liver cells. Hepatology (1994) 1.63
Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology (1997) 1.63
Complications and risk factors after ileal pouch-anal anastomosis for ulcerative colitis associated with primary sclerosing cholangitis. Ann Surg (1993) 1.63
Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology (1996) 1.62
Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue. Chest (1993) 1.61
Pelvic prolapse: assessment with evacuation proctography (defecography) Radiology (1992) 1.61
Copper and primary biliary cirrhosis. Gastroenterology (1974) 1.59
Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. Mayo Clin Proc (1993) 1.59
Clinical and radiologic features of cerebral edema in fulminant hepatic failure. Mayo Clin Proc (1995) 1.59
Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc (1994) 1.59
Dynamics of the enterohepatic circulation of bile acids. Postprandial serum concentrations of conjugates of cholic acid in health, cholecystectomized patients, and patients with bile acid malabsorption. N Engl J Med (1974) 1.58
De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant (2014) 1.57
Designs for group sequential phase II clinical trials. Biometrics (1987) 1.57
Rapid dissolution of gallstones by methyl tert-butyl ether. Preliminary observations. N Engl J Med (1985) 1.57
Development and characterization of polarized primary cultures of rat intrahepatic bile duct epithelial cells. Lab Invest (1996) 1.56
Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology (2000) 1.55